MedTrace Logo

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

NCT02431052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2021-07-20

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Olumacostat Glasaretil

OTHER

Vehicle

Sponsors & Collaborators

  • Dermira, Inc.

    lead INDUSTRY

Principal Investigators

  • Beth Zib · Dermira, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431052 on ClinicalTrials.gov